Abstract
Objectives To investigate if there was an increase in menstrual abnormality related presentation post COVID-19 vaccination.
Design BERTopic machine learning, with a guided topic modelling option was used to analyse mentions of menstrual change in relation to COVID-19 vaccination on the social media platform Reddit. Self-controlled case series (SCCS) analysis using general practice data collected via the POpulation Level Analysis and Reporting (POLAR) tool with permission from Primary Health Networks (PHNs) as the de-identified dataset owners in Victoria and New South Wales.
Setting Globally for social media analysis. Victoria and New South Wales (NSW), Australia for POLAR
Participants For social media analysis, people who made a Reddit post about menstrual concerns post COVID-19 vaccine. For the SCCS analysis, people who presented to a POLAR GP registered practice with a new menstrual abnormality diagnosis.
Exposures COVID-19 vaccination with adenovirus vector [AstraZeneca’s Vaxzervria® ChadOx1-S], mRNA [Pfizer-BioNTech’s Comirnaty® BNT162b2 and Moderna’s Spikevax®] or protein-subunit [Novavax’s Nuvaxovid®]).
Outcomes and Measures Scraped social media posts were pre-processed, analysed for positive, negative, and neutral sentiments and topic modelled. Menstrual abnormality presentations of interest were isolated from the general practice dataset aggregated by POLAR, by searching for relevant SNOMED CT codes. Similarly, relative incidence (RI) was calculated for all COVID-19 vaccine types.
Results Social media analysis saw peaks in menstrual change posts on Reddit since the global COVID-19 vaccine rollout. The SCCS analysis demonstrates an increase in general practice presentations of menstrual abnormality diagnosis following mRNA vaccines (RI= 1.14, 95% CI: 1.07 to 1.22, P <0.001).
Conclusions and Relevance This study demonstrates an increase in menstrual abnormality presentations following COVID-19 mRNA vaccination. Our findings validate the concerns raised on social media so people who are vaccinated or are considering future vaccines feel heard, supported, and validated. Our analysis highlights the importance of using large real-world datasets to gather reliable evidence for public health decision making.
Section 1: What is already known on this topic?
Section 1: What is already known on this topic?
Surveys and spontaneous surveillance systems suggested and association of menstrual cycle changes with COVID-19 vaccination.
Heavy menstrual bleeding was added to the product information for mRNA vaccines in the European Union
Section 2: What this study adds?
Section 2: What this study adds?
Our study is the first to prove an increase in menstrual abnormality related presentations post mRNA COVID-19 vaccines using routinely collected general practice data.
Our findings validate the concerns raised by people who menstruate and help them with their future decision to vaccinate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SAEFVIC, is funded by the Department of Health, Victoria for provision of state-wide vaccine safety services including continuous improvement in methods for vaccine vigilance and investigation of vaccine safety concerns. The Department is not involved in collection, analysis, interpretation of data; writing of the report; or decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Monash Human Research Ethics Committee [RES-18-0000-232A].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No additional data available.
